C16orf74 Blocker for Pancreatic Cancer Therapy

Blocking C16orf74 dimerization suppresses pancreatic cancer growth and invasion.

Advantages and Core Benefit

  • C16orf74 homodimer is a novel therapeutic target against pancreatic cancer.
  • Our peptide blocking C16orf74 dimerization demonstrates significant anti-cancer effect in vivo.
  • Middle molecular compound blocking the dimerization can be identified or designed by using C16orf74 dimer and our peptide.

Background and Technology

Pancreatic ductal adenocarcinoma (PDAC) reveals worse prognosis than any other types of malignant tumor. Although some therapies have been developed for pancreatic cancer such as FOLFIRINOX, EGFR TKI and mAbs, they have not showed enough therapeutic effect to date.

We investigated expression profiles of PDACs using a genome-wide cDNA microarray with pure populations of cancer cells and have identified C16orf74 that is frequently over-expressed in pancreatic cancer specimens. (Nakamura T, et al., Oncotarget. 2017; 8:50460-50475.) The C16orf74 has been reported as Homo sapiens chromosome 16 open reading frame 74 and is located on chromosome 16q24.1. This gene was shown to be associated with TNF-alpha as well as hypoxic condition. Moreover, several reports have indicated that C16orf74 expression is a potential prognostic factor in several types of cancer.

Here, we have found out that intracellular C16orf74 homodimer interacts with the protein phosphatase 3 catalytic subunit alpha (PPP3CA) and is indispensable for invasion and proliferation of PDAC cells. Our peptide blocking dimerization of C16orf74 and interaction between C16orf74 and PPP3A suppressed PDACs proliferation and invasion.

無題

Data and Publication

– PK-9 (human pancreatic ductal adenocarcinoma cell-line) orthotopic mice (n=6)
– 11R*-DB: therapeutic peptide, 11R-7_14AAA: negative control peptide
*The 11R is used as an enhancer for intracellular uptake of the peptide
– i.p. administration, 5 times/week, 1 week after PK-9 injection
– Analyzed by in vivo imaging until 35 days after PK-9 injection, then scarified to observe tumor weight and other organs
– No body weight reduction and side effect

ああ あああ

<Reference>

“Overexpression of C16orf74 is involved in aggressive pancreatic cancers”, Oncotarget, 2017, Vol. 8, (No. 31), pp: 50460-50475

“Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation”, Oncotarget, 2017, Vol. 8, (No. 69), pp: 113662-113672

Patent

PCT International Application; WO2019/050036

Researcher

Toru Nakamura, et al., Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Product No.: CD-02710

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.